XPA, XPC, and XPD Modulate Sensitivity in Gastric Cisplatin Resistance Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cisplatin is a key drug for advanced gastric cancer but faces challenges due to tumor heterogeneity and drug resistance.
• Varied patient responses to cisplatin necessitate understanding the molecular mechanisms driving treatment sensitivity and resistance.

Purpose of the Study:

• To investigate the molecular pathways of cisplatin-induced apoptosis in two gastric cancer cell lines (AGS and MKN45) with differing sensitivities.
• To identify key molecular differences contributing to cisplatin sensitivity in MKN45 cells compared to AGS cells.

Main Methods:

• Comparative analysis of apoptosis induction by cisplatin (CDDP) in AGS and MKN45 gastric cancer cell lines.
• Examination of the intrinsic apoptotic pathway, focusing on Bcl-2 family proteins (Mcl-1, Bid, Bad).
• Assessment of the DNA repair Nucleotide Excision Repair (NER) pathway, including XPC, XPA, and XPD protein activity.

Main Results:

• MKN45 cells exhibited higher cisplatin-induced apoptosis than AGS cells.
• In MKN45 cells, cisplatin treatment led to Mcl-1 degradation and increased Bid and Bad levels, enhancing sensitivity.
• Impaired NER pathway in MKN45 cells was observed, characterized by low XPC levels and lack of XPA/XPD nuclear translocation.

Conclusions:

• The intrinsic apoptotic pathway and NER pathway are critical in determining cisplatin sensitivity in gastric cancer.
• Targeting Bcl-2 family proteins and the NER pathway presents a promising strategy to enhance cisplatin treatment efficacy in gastric cancer.